Use of omalizumab as adjuvant therapy in AIT for respiratory allergies

ReferenceStudy typeAllergenPatientsMain results/aims
Kuehr et al. [8], 2002RCT, DBPCGrass, birch221Combined therapy outperforms either component alone in terms of the symptom score and the rescue medication score.
Casale et al. [9], 2006RCT, DBPCRagweed159Omalizumab before treatment showed a five-fold reduction in the risk of rush anaphylaxis associated with SCIT. The use of combination therapy was associated with a decrease in the intensity of symptoms compared to SCIT alone.
Kopp et al. [10], 2009RCT, DBPCGrass140Combination therapy led to a decrease in daily symptom scores, an improvement in QoL and in the management of rhinoconjunctivitis and asthma.
Massanari et al. [11], 2010RCT, DBPCMite, cat, dog225Omalizumab before treatment correlated with a decreased occurrence of systemic reactions and an increased chance of reaching the maintenance SCIT dose.
Stelmach et al. [12], 2015RCT, DBPCMite, moulds7Consecutive combination therapy resulted in the reduction of exacerbation frequency and hospitalizations. Significant decrease in the utilization of steroids was observed.
Valdesoiro-Navarrete et al. [13], 2022Retrospective studyMite, Alternaria, and pollens29Combination therapy resulted in a significant improvement of asthma control score (CAN questionnaire) and forced expiratory volume in one second (FEV1), following a year of treatment.

RCT: randomized controlled trial; SCIT: subcutaneous immunotherapy; QoL: quality of life